BACKGROUND & AIMS: Tumor and viral antigens are expressed by hepatocellular
carcinoma (HCC) in patients with chronic hepatitis B, but little is known about the …

Simple Summary TP53 is the most frequently mutated gene in many cancers, but it has
failed to be a very effective target for treatment to date. To overcome this, we have examined …

The tumor suppressor protein p53 is overexpressed in close to 50% of all human
malignancies. The p53 protein is therefore an attractive target for immunotherapy. Cytotoxic …

T cell surveillance is often effective against virus-associated tumors because of their high
immunogenicity. It is not clear why surveillance occasionally fails, particularly against …

The p53 protein is markedly up-regulated in a high proportion of human malignancies.
Using an HLA-A2 transgenic mouse model, it was possible to isolate high-avidity murine …

The BALB/c Meth A sarcoma carries a p53 missense mutation at codon 234, which occurs in
a peptide, termed 234CM, capable of being presented to cytotoxic T lymphocytes (CTL) by H …

In many types of cancer, p53 frequently accumulates in tumor cells and anti-p53 antibodies
can be detected. However, only four CD8+ T-cell epitopes from p53 have been identified in …

We analyzed CD4+ T helper responses to wild-type (wt) and mutated (mut) p53 protein in
normal and tumor-bearing mice. In normal mice, we observed that although some self-p53 …

Immune checkpoint inhibitors are groundbreaking resources for cancer therapy. However,
only a few patients with hepatocellular carcinoma (HCC) have shown positive responses to …

Mutation of the tumor‐suppressor gene p53 is involved in carcinogenetics. We investigated
the role of p53 in the induction of anti‐tumor immune responses by establishing a thyroid …